@ARTICLE{
author={Tiede Andreas,Rosa Cid Ana,Goldmann Georg,Jimenez-Yuste Victor,Pluta Michael,Lissitchkov Toshko,May Marcus,Matytsina Irina,Miljic Predrag S,Pabinger Ingrid,Persson Paula},
year={2020},
title={Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A},
journal={THROMBOSIS AND HAEMOSTASIS},
volume={120},
number={2},
pages={277-288},
document_type={Article},
} 

@ARTICLE{
author={Tiede Andreas,Goldmann Georg,Miljic Predrag S,Korsholm Lars,Matytsina Irina,Persson Paula,Jelev Lissitchkov Toshko},
year={2018},
title={A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A},
journal={BLOOD},
volume={132},
number={},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Lentz Steven R,Janic Dragana M,Kavakli Kaan,Miljic Predrag S,Oldenburg Johannes,Ozelo Margareth Castro,Santagostino Elena,Suzuki Takashi,Zupancic-Salek Silva,Korsholm Lars,Matytsina Irina,Tiede Andreas},
year={2018},
title={Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial},
journal={HAEMOPHILIA},
volume={24},
number={6},
pages={E391-E394},
document_type={Article},
} 

@ARTICLE{
author={Tiede Andreas,Janic Dragana M,Ozelo M,Santagostino E,Korsholm Lars,Matytsina Irina,Lentz SR},
year={2018},
title={Use of turoctocog alfa for less-frequent prophylaxis in selected patients has comparable efficacy with the overall prophylaxis cohort in Guardian (TM) 2},
journal={HAEMOPHILIA},
volume={24},
number={},
pages={52-52},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Lentz SR,Cerqueira MH,Janic Dragana M,Kempton CL,Matytsina Irina,Misgav M,Oldenburg J,Ozelo M,Recht M,Rosholm A,Savic Aleksandar D,Suzuki Takashi,Tiede Andreas,Santagostino E},
year={2016},
title={Interim results from a large multinational extension trial (guardian (TM) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A},
journal={HAEMOPHILIA},
volume={22},
number={5},
pages={E445-E449},
document_type={Letter},
} 

@ARTICLE{
author={Janic Dragana M,Karim Faraizah Abdul,Matytsina Irina,Ozelo Margareth Castro,Savic Aleksandar D,Tiede Andreas,Oldenburg Johannes},
year={2016},
title={Efficacy and safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients with severe hemophilia A: results from the guardian (TM) 2 trial},
journal={HAEMOPHILIA},
volume={22},
number={},
pages={48-48},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Lentz SR,Kempton CL,Janic Dragana M,Savic Aleksandar D,Cerqueira MH,Ozelo MC,Recht M,Oldenburg J,Tiede Andreas,Suzuki Takashi,Matytsina Irina,Zeuthen N,Santagostino E},
year={2015},
title={Interim results from a large multinational extension trial (Guardian TM2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A},
journal={JOURNAL OF THROMBOSIS AND HAEMOSTASIS},
volume={13},
number={},
pages={842-842},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Lentz SR,Misgav M,Ozelo MC,Salek SZ,Veljkovic Dobrila K,Recht M,Cerqueira MH,Tiede Andreas,Brand B,Mancuso ME,Seremetis S,Lindblom A,Martinowitz U},
year={2013},
title={Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy},
journal={HAEMOPHILIA},
volume={19},
number={5},
pages={691-697},
document_type={Article},
} 

@ARTICLE{
author={Lentz SR,Misgav M,Ozelo MC,Zupancic-Salek Silva,Veljkovic Dobrila K,Recht M,Cerqueira MH,Tiede Andreas,Brand B,Mancuso ME,Martinowitz U},
year={2012},
title={Safety and efficacy of turoctocog alfa during prevention and treatment of bleeds in adult and adolescent patients with severe haemophilia A},
journal={HAEMOPHILIA},
volume={18},
number={5},
pages={829-830},
document_type={Meeting Abstract},
}